Ascendis Pharma's last quarter came with a sweetener that will not repeat. The sale of a priority review voucher for $187.5 million added roughly 158 million euros of other operating income and inflated earnings to $3.29 a share. When the Danish drugmaker reports third-quarter results before the market opens on November 12, the numbers will have to stand on product sales alone. That makes this the cleanest read yet on whether a three-product commercial engine can carry the profitability story management laid out last quarter.
Wall Street expects earnings of $1.13 a share on revenue of about $417.2 million. The comparison with a year ago is striking. Ascendis lost $1.17 a share in the same quarter last year on revenue of $249.7 million, so consensus implies revenue growth of about 67% and a swing of nearly 197% in earnings. The sequential step is more modest: revenue would rise roughly 6% from the $394.4 million reported last quarter. That is not a demanding bar for a company whose lead launch was still accelerating sharply as of midyear. Management has not issued a quarterly revenue forecast, but it reaffirmed full-year operating cash flow of more than 500 million euros and described the upside from the UVWell launch as open-ended. Results that keep that cash target comfortably in reach would support the claim.
YorvaPath remains the core of the case. Quarterly sales climbed from 143 million euros a year ago to 252 million euros in the second quarter, partly helped by the reversal of about 15 million euros of one-time drags that had weighed on the first quarter. With that catch-up now in the base, the third quarter shows the drug's underlying growth rate. Another solid sequential gain would show the blockbuster run rate is real rather than flattered by timing. A flat result would put a spotlight on the US-only problem management flagged. Patients have been dropping off during the dose-titration phase, which has required more costly patient support. Commentary on whether that extra support is reducing dropouts will matter as much as the headline number.
UVWell, the achondroplasia treatment approved in February, is the newer test. It generated only 8 million euros in its first quarter on the market. Still, enrollments rose from about 170 at the end of June to more than 220 by the end of July, and over 65% of patients had secured reimbursement approval. Management argued the drug is expanding the market and is on track to lead it in the US. This quarter should show whether those enrollments are turning into paid prescriptions at a pace that justifies that confidence. Skytropha, which had been steady in the mid-50 million euro range, needs only to avoid another dip like the first quarter's.
Costs are the other swing factor. Selling and administrative expenses rose from 145 million to 173 million euros in the second quarter as launches ramped, while the non-IFRS operating margin still improved from 22% to 27%. Further margin expansion would confirm that operating leverage is kicking in. A margin step back would raise questions about how expensive these launches really are. Management should also update investors on the BioMarin patent dispute at the International Trade Commission, where an initial judge's opinion was expected in August and a full commission decision is due in December. It also owes an update on the European decision for UVWell expected this quarter.
Sentiment has warmed noticeably, with bullish readings rising to about 39% from 13% ahead of the prior report. The stock is up about 1% since last quarter's results while the S&P 500 fell more than 5%. At around $253, shares sit above their 200-day average but roughly 7% below the post-earnings high of $272.47, so expectations are firm without being stretched. The central question is simple: without the voucher windfall, can YorvaPath's growth and UVWell's conversion of enrollments into revenue deliver profits that look like a durable franchise rather than a one-quarter event?